Last reviewed · How we verify
Ad26.Mos.HIV
HIV vaccine
HIV vaccine Used for HIV prevention.
At a glance
| Generic name | Ad26.Mos.HIV |
|---|---|
| Sponsor | Janssen Vaccines & Prevention B.V. |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
Ad26.Mos.HIV is a recombinant adenovirus vector-based vaccine designed to elicit an immune response against HIV.
Approved indications
- HIV prevention
Common side effects
Key clinical trials
- Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (PHASE1, PHASE2)
- Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults (PHASE1, PHASE2)
- Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention (PHASE1, PHASE2)
- Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad26.Mos.HIV CI brief — competitive landscape report
- Ad26.Mos.HIV updates RSS · CI watch RSS
- Janssen Vaccines & Prevention B.V. portfolio CI